Encyclopedia of contested claims
Ozempic and related semaglutide medicines are associated with weight loss while treatment continues, but available evidence indicates that weight regain is common after stopping. The degree of regain varies by person, dose, duration, lifestyle support, and underlying health conditions.
8 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its review of this claim. This draft summarizes the main evidence likely to be considered, identifies sub-claims for evaluation, and lists source candidates for later verification and citation.
Ozempic and related semaglutide medicines are associated with weight loss while treatment continues, but available evidence indicates that weight regain is common after stopping. The degree of regain varies by person, dose, duration, lifestyle support, and underlying health conditions.
The claim asks whether Ozempic causes sustained weight loss after discontinuation. Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist approved in many jurisdictions for type 2 diabetes treatment. Semaglutide is also sold at different doses and under different brand names for chronic weight management.
The key issue is not whether people can lose weight while using semaglutide. Clinical trials and clinical experience indicate that many patients lose weight during treatment. The question is whether that weight loss typically continues or remains largely intact after the drug is stopped.
This distinction matters because semaglutide acts partly by reducing appetite, increasing satiety, and affecting metabolic signaling while it is being taken. If those drug effects are removed, appetite and weight-regulation pressures may return toward prior patterns.
The strongest directly relevant evidence comes from semaglutide withdrawal studies and follow-up extensions. In the STEP 1 trial extension, participants who had received semaglutide 2.4 mg and lifestyle intervention regained a substantial portion of the weight they had lost during treatment after semaglutide was withdrawn. The published follow-up reported that, on average, participants regained about two-thirds of their prior weight loss over the following year.
Another relevant trial, STEP 4, included a run-in period in which participants received semaglutide and then were randomized either to continue semaglutide or switch to placebo. Those who continued treatment generally kept losing weight, while those switched away from semaglutide tended to regain weight during the randomized period.
These findings fit the broader view of obesity as a chronic, relapsing condition in which biological mechanisms can favor weight regain after weight loss. For many patients, medication appears to function as ongoing treatment rather than a short course that permanently resets body weight.
That does not mean every person regains all lost weight after stopping. Some people may maintain part of their weight loss with dietary changes, physical activity, other medications, surgery, or continued clinical support. But the available trial evidence does not support the broad claim that Ozempic by itself usually causes sustained weight loss after discontinuation.
Most direct withdrawal evidence involves semaglutide 2.4 mg used for obesity treatment, commonly associated with Wegovy, rather than Ozempic doses used for diabetes. Because the active ingredient is the same but dosing and patient populations can differ, Ozempic-specific discontinuation outcomes may not be identical.
Longer-term real-world data are still developing. Trial participants may differ from routine-care patients in adherence, follow-up, lifestyle support, insurance coverage, and reasons for stopping treatment. These differences could affect how much weight is regained and over what time period.
There is also uncertainty about which strategies best preserve weight loss after stopping semaglutide. Maintenance may depend on individualized nutrition support, resistance training, behavioral treatment, management of diabetes or other conditions, and whether another anti-obesity treatment is used.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 82% | No · 88% | No · 68% | No · 90% |
| Mistral Medium 3.5 | No · 82% | No · 88% | No · 68% | No · 90% |
| Llama 4 Maverick | No · 82% | No · 88% | No · 68% | No · 80% |
| OpenAI GPT-5.4 | No · 82% | No · 88% | No · 68% | No · 90% |
| Claude Opus 4.7 | No · 82% | No · 88% | No · 68% | No · 90% |
| Gemini 3.1 Pro | — | — | — | Incomplete |
| DeepSeek V4 Pro | No · 82% | No · 88% | No · 68% | No · 90% |
| GLM 5.1 | No · 82% | No · 88% | No · 68% | No · 90% |
| Qwen 3.7 Max | No · 82% | No · 88% | No · 68% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
No, Ozempic (semaglutide) does not produce sustained weight loss after discontinuation for the majority of users. Clinical trial data, including the STEP 1 extension, show average weight regain of roughly two-t...
No, Ozempic (semaglutide) does not typically cause sustained weight loss after discontinuation. Most evidence indicates that weight regain is common after stopping the medication, though the extent varies by in...
Ozempic, a semaglutide medication, is associated with weight loss during treatment, but evidence suggests that weight regain is common after discontinuation. The degree of weight regain varies depending on fact...
Mostly no. Semaglutide/Ozempic reliably causes weight loss during treatment, but the best available evidence indicates that after discontinuation, average weight regain is common rather than sustained maintenance of most lost weight. Confidence: High. Key evidence: - The STEP 1 extension study directly examined what happened after stopping semaglutide 2.4 mg. Participants had lost substantial weight during 68 weeks of treatment, then after stopping regained a large portion of that loss over the following year. On a...
No. The available evidence indicates that semaglutide (Ozempic/Wegovy) does not produce sustained weight loss after discontinuation for most people; substantial weight regain is the typical pattern. Confidence:...
Incomplete response: output limit reached before the answer finished.
No, Ozempic (semaglutide) does not cause sustained weight loss after discontinuation for most people. The predominant finding from clinical trials is that weight regain is common once treatment stops. **Confide...
No. Ozempic (semaglutide) does not cause sustained weight loss after discontinuation. Available clinical evidence demonstrates that weight regain is the typical outcome once the medication is stopped. Confidenc...
No, Ozempic (semaglutide) does not typically cause sustained weight loss after discontinuation; clinical evidence indicates that significant weight regain is the norm once the medication is stopped. My confiden...
